August 02, 2014 12:39 AM ET

Healthcare Providers and Services

Company Overview of Enzo Clinical Labs, Inc.

Company Overview

Enzo Clinical Labs, Inc. operates clinical reference laboratories in the United States. It offers various assays in the areas of chemistry, fertility and hormone studies, pregnancy, hematology, and coagulation. The company also provides electronic report delivery services for physicians. In addition, it offers phlebotomy services for patients needing blood tests through its network of patient service centers; diagnostic test that assists in risk assessment and early detection of lung cancer; and ColonSentry, a blood test to assess an individual's current risk for colorectal cancer. Enzo Clinical Labs, Inc. is based in Farmingdale, New York. The company has patient service centers in Manhatta...

60 Executive Boulevard

Farmingdale, NY 11735

United States

Phone:

631-755-5500

Fax:

631-755-5561

Key Executives for Enzo Clinical Labs, Inc.

Chairman of the Board and Chief Executive Officer
Age: 71
President of Enzo Biochem Inc
Age: 64
Medical Director
Vice President of Corporate Development
Age: 57
Scientific Director and Associate Medical Director
Compensation as of Fiscal Year 2014.

Enzo Clinical Labs, Inc. Key Developments

Enzo Clinical Labs and Nuclea Biotechnologies Join to Market New Test for Certain High Risk Breast Cancer Patients

Enzo Biochem Inc. announced that its Enzo Clinical Labs subsidiary and Nuclea Biotechnologies, Inc. have entered into a non-exclusive distribution agreement to market Nuclea's non-invasive HER-2/neu serum test, a key assay in the monitoring of metastatic breast cancer. This blood test facilitates the monitoring and treatment decisions of women with metastatic breast cancer that over expresses the HER-2/neu protein in the tumor. Individuals with this condition tend to have a worse prognosis and a more aggressive disease that can resist certain types of chemotherapy. The test measures the portion of HER-2/neu protein that lies outside the surface of the cell and being released into the blood stream, allowing for more informed treatment decisions for a number of women who may not be responding to breast cancer treatment or may be at risk for metastatic cancer and need revised treatment plans. Utilizing the HER-2/neu blood test while monitoring the disease's progression will enable physicians to better adapt, combine therapies and change treatment protocols. Studies have demonstrated that use of combination chemotherapy regimens provides a statistically significant advantage for survival and tumor response in women with metastatic breast cancer.

The Enzo Clinical Labs. and Sequenom Laboratories, Inc. Partner to Market Key Sequenom Laboratories Prenatal Testing Service

The Enzo Clinical Labs entered into an agreement to market in its northeast U.S. service area a proprietary early non-invasive prenatal laboratory test service, MaterniT21 PLUS (TM), developed by the Sequenom Laboratories, Inc.

Enzo Biochem's Enzo Clinical Labs, Inc. Introduces Diagnostic Test That Assists in Early Detection of Lung Cancer

Enzo Biochem Inc. announced that its Enzo Clinical Labs, Inc. has introduced a new diagnostic test that assists in risk assessment and early detection of lung cancer. It is being made available to physicians in the New York metropolitan market as well as New Jersey and Eastern Pennsylvania, where Enzo is the only clinical laboratory making the test available within those areas. EarlyCDT-Lung has been approved by the New York State Department of Health. Utilizing a simple blood specimen, the test is directed at patients with a high risk of developing lung cancer, including heavy smokers, those exposed to suspect environmental conditions, and patients with a CT nodule under surveillance. The availability of EarlyCDT-Lung by Enzo Clinical Labs is the result of an agreement with its developer, Kansas-based Oncimmune(R). The agreement provides for Enzo to be the only clinical laboratory located within its marketing area to make the test available to physicians. EarlyCDT-Lung uses a panel of tumor antigens that are selected for their involvement in the development of lung cancer. Autoantibodies form and circulate in the body at all stages of the disease including Stages I and IIA, which are the earliest stages of lung cancer. Their measurement may signify the presence of cancerous cells. The Oncimmune immuno-biomarker platform (EarlyCDT-Lung) provides increased sensitivity while maintaining higher levels of specificity than other single or multiple antigen tests. Elevation above a predetermined cutoff value of any one immuno-biomarker of the panel suggests that a tumor might be present. While risk assessment and early detection of lung cancer in asymptomatic high-risk patient populations are the primary benefits of EarlyCDT-Lung, it is also valuable as a follow-up test for high-risk patients who have indeterminate lung nodules identified by CT.

Similar Private Companies By Industry

Company Name Region
St. Joseph Health Center United States
1st Choice Home Health Care LLC United States
Huguley Surgery Center, L.L.P. United States
Resp-I-Care, Inc. United States
Monongalia Health System, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Enzo Clinical Labs, Inc., please visit www.enzo.com/clinicallabs/index.asp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.